Medindia
Medindia LOGIN REGISTER
Advertisement

NKTR-102 Has High Response Rate and Sustained Clinical Benefit in 48 Percent of Women with Platinum-Resistant/Refractory Ovarian Cancer

Sunday, June 6, 2010 General News
Advertisement
Phase 2 Data Highlighted in Oral Abstract Session of 2010 American Society of Clinical Oncology Annual Meeting

Nektar Investor Inquiries:

Jennifer Ruddock/Nektar Therapeutics

(650) 631-4954

Susan Noonan/S.A. Noonan Communications

(212) 966-3650

Nektar Media Inquiries

Karen Bergman/BCC Partners

(650) 575-1509

Michelle Corral/BCC Partners

(415) 794-8662

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close